The NHS in England and Wales has approved teplizumab, described by multiple outlets as the first treatment able to delay the onset of type 1 diabetes. Coverage reports that the National Institute for Health and Care Excellence (NICE) has given the drug approval for NHS use, with Diabetes UK and other commentators characterising it as a major step forward in treatment. Teplizumab is designed to target the autoimmune process that affects the pancreas, which leads to insulin deficiency in type 1 diabetes.
Several reports state that teplizumab can postpone the start of the condition by up to three years on average, giving time before full symptoms of type 1 diabetes develop. The announcement is presented as particularly significant for children and teenagers at risk, since type 1 diabetes commonly emerges during childhood or adolescence. While outlets vary in emphasis, the common points are that teplizumab is first-in-class for delaying onset, has received NHS approval through the NICE process, and is expected to be rolled out in England and Wales after the regulatory decision. The reports do not indicate that the drug prevents type 1 diabetes entirely, only that it delays its onset.
